DJIA 16,643.01 -11.76 -0.07%
NASDAQ 4,828.33 15.62 0.32%
S&P 500 1,988.87 1.21 0.06%
market minute promo

10.50 0.07 (0.67%)

Quote as of


company name or ticker

Recent Quotes

MACK $10.50 0.67%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $10.31
Previous Close $10.43
Daily Range $10.31 - $11.00
52-Week Range $6.38 - $13.84
Market Cap $1.2B
P/E Ratio -11.72
Dividend (Yield) $0.00 (0.0%)
Volume 2,617,481
Average Daily Volume 1,570,933
Current FY EPS -$1.06

Sector

Healthcare

Industry

Drug Makers

Merrimack Pharmaceuticals, Inc. (MACK) Description

Merrimack Pharmaceuticals Inc is a biopharmaceutical company discovering developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases with an initial focus on cancer. Website: http://www.merrimackpharma.com/

News & Commentary

Why Merrimack Pharmaceuticals Inc is Soaring Today

Investors cheer a smaller than expected loss and wait patiently for news about regulatory approval of MM-398.

Merrimack Pharmaceuticals (MACK) Is Today's Dead Cat Bounce Stock

10 Biotech Stocks With Catalysts Coming Soon

Friday 8/14 Insider Buying Report: SHLM, MACK

Merrimack Pharmaceuticals (MACK) Catches Eye: Stock Up 5.8%

Merrimack Pharmaceuticals' Q2 Loss Wider, Revenues Up - Analyst Blog

Merrimack Pharmaceuticals' (MACK) CEO Bob Mulroy on Q2 2015 Results - Earnings Call Transcript

Earnings Reaction History: Merrimack Pharmaceuticals Inc, 25.0% Follow-Through Indicator, 7.2% Sensi

Earnings Reaction History: Merrimack Pharmaceuticals Inc, 25.0% Follow-Through Indicator, 7.2% Sensitive

Merrimack Pharmaceuticals (MACK): Q2 Earnings Preview - Analyst Blog

Merrimack Pharmaceuticals' Stock Tanked in July: Is It Now a Buy?

Shares of Merrimack Pharmaceuticals slumped in July by double digits. Does this huge dip represent a compelling buying opportunity?

See More MACK News...